We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

126 hedge funds and large institutions have $961M invested in Applied Therapeutics in 2024 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 33 increasing their positions, 31 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 15

99% more capital invested

Capital invested by funds: $482M → $961M (+$479M)

34% more funds holding

Funds holding: 94126 (+32)

7.78% more ownership

Funds ownership: 90.38%98.16% (+7.8%)

6% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 31

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

2% less call options, than puts

Call options by funds: $17.1M | Put options by funds: $17.5M

Holders
126
Holders Change
+32
Holders Change %
+34.04%
% of All Funds
1.81%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
47
Increased
33
Reduced
31
Closed
15
Calls
$17.1M
Puts
$17.5M
Net Calls
-$352K
Net Calls Change
-$4.88M
Name Holding Trade Value Shares
Change
Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$6.47M +$3.11M +527,276 +226%
Charles Schwab
27
Charles Schwab
California
$6.25M +$2.7M +457,940 +165%
SCM
28
Soleus Capital Management
Connecticut
$5.79M -$3.47M -588,930 -46%
PCM
29
Peregrine Capital Management
Minnesota
$5.65M -$391K -66,308 -9%
ABG
30
Ally Bridge Group
New York
$5.26M +$3.64M +618,332 New
Invesco
31
Invesco
Georgia
$4.76M +$3.03M +514,357 +1,136%
Marshall Wace
32
Marshall Wace
United Kingdom
$4.54M +$3.15M +534,004 New
Citadel Advisors
33
Citadel Advisors
Florida
$3M +$1.63M +277,030 +362%
SSA
34
Schonfeld Strategic Advisors
New York
$2.91M -$1.13M -191,219 -36%
Bank of America
35
Bank of America
North Carolina
$2.68M +$501K +85,044 +37%
SFM
36
Sphera Funds Management
Israel
$2.65M -$2.14M -362,696 -54%
UBS Group
37
UBS Group
Switzerland
$2.41M +$658K +111,622 +65%
Millennium Management
38
Millennium Management
New York
$2.36M +$981K +166,462 +150%
HWAM
39
Hennion & Walsh Asset Management
New Jersey
$2.26M +$403K +68,330 +35%
N
40
Nuveen
North Carolina
$2.22M -$60.1K -10,193 -4%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$2.09M -$220K -37,347 -13%
AQR Capital Management
42
AQR Capital Management
Connecticut
$1.86M +$1.29M +218,518 New
Macquarie Group
43
Macquarie Group
Australia
$1.78M -$117K -19,812 -9%
T. Rowe Price Investment Management
44
T. Rowe Price Investment Management
Maryland
$1.76M +$1.22M +207,550 New
Wellington Management Group
45
Wellington Management Group
Massachusetts
$1.72M +$1.19M +201,966 New
Barclays
46
Barclays
United Kingdom
$1.7M +$767K +130,102 +186%
WAG
47
Windsor Advisory Group
Ohio
$1.69M +$1.17M +198,987 New
Group One Trading
48
Group One Trading
Illinois
$1.36M +$944K +160,164 New
Rafferty Asset Management
49
Rafferty Asset Management
New York
$1.35M +$939K +159,262 New
Rockefeller Capital Management
50
Rockefeller Capital Management
New York
$1.27M

APLT Hedge Fund Activity: Q3 2024 in Review

126 of the 6,966 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q3 2024, worth a combined $961M — up 99% from $482M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new APLT positions and 15 closed out — a net gain of 32 holders — while 33 added to existing stakes and 31 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $37.6M. The largest seller was Vestal Point Capital, cutting an estimated $25.3M.

  • 126 institutional investors held Applied Therapeutics (APLT) as of Q3 2024, up from 94 in Q2 2024.
  • Funds reported $961M of Applied Therapeutics stock for Q3 2024, up 99% quarter-over-quarter.
  • 47 funds opened new Applied Therapeutics positions in Q3 2024 and 15 closed out, a net change of +32 holders.
  • The largest Applied Therapeutics buyer in Q3 2024 was Morgan Stanley, an estimated $37.6M added.
  • The largest Applied Therapeutics seller in Q3 2024 was Vestal Point Capital, an estimated $25.3M sold.

Based on aggregated 13F filings for Q3 2024.